{"entity":{"id":"nct03260023","kind":"trial","name":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","aka":[],"tldr":"A phase 1/2 trial of Avelumab in penile cancer, run by Transgene, active and no longer recruiting.","summary":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers is a phase 1/2 interventional study registered as NCT03260023 by Transgene, with 143 participants enrolled, started 2017-09-01 and due to reach its primary completion in 2024-09-18. Interventions recorded: TG4001, Avelumab. Conditions listed: HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03260023","url":"https://clinicaltrials.gov/study/NCT03260023"}],"tags":["ctgov-ingest"],"related":[],"cancers":["penile"],"sections":[],"technologies":[],"targets":[],"drugs":["avelumab"],"companies":["transgene"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03260023","phase":"1/2","setting":"A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.","sponsor":"Transgene","enrolled":143,"outcomes":[]},"route":"/trials/nct03260023/","neighbours":{"cancer":[{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/"}],"drug":[{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/"}],"company":[{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/"}]}}